{
  "Disease activity (follow up: 4 months; assessed with: ACR 20)": {
    "No of studies": [
      "5"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": [
      "very serious",
      "b"
    ],
    "Other considerations": "none",
    "No of patients": {
      "Switch to a 2nd TNFi": [
        "8/13 (61.5%)",
        "c"
      ],
      "Continue 1st TNFi": [
        "4/14 (28.6%)",
        "d"
      ]
    },
    "Effect": {
      "Relative (95% CI)": "RR 2.15 (0.85 to 5.48)",
      "Absolute (95% CI)": "329 more per 1,000 (from 43 fewer to 1,000 more)"
    },
    "Certainty": "  VERY LOW",
    "Importance": "CRITICAL"
  },
  "Disease activity (follow up: 4 months; assessed with: ACR 50)": {
    "No of studies": [
      "5"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": [
      "very serious",
      "b"
    ],
    "Other considerations": "none",
    "No of patients": {
      "Switch to a 2nd TNFi": [
        "4/13 (30.8%)",
        "c"
      ],
      "Continue 1st TNFi": [
        "2/14 (14.3%)",
        "d"
      ]
    },
    "Effect": {
      "Relative (95% CI)": "RR 2.15 (0.47 to 9.85)",
      "Absolute (95% CI)": "164 more per 1,000 (from 76 fewer to 1,000 more)"
    },
    "Certainty": "  VERY LOW",
    "Importance": "CRITICAL"
  },
  "Disease activity (follow up: 4 months; assessed with: DAS28-ESR)": {
    "No of studies": [
      "5"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": [
      "very serious",
      "e"
    ],
    "Other considerations": "none",
    "No of patients": {
      "Switch to a 2nd TNFi": [
        "13",
        "c"
      ],
      "Continue 1st TNFi": [
        "14",
        "d"
      ]
    },
    "Effect": {
      "Relative (95% CI)": "-",
      "Absolute (95% CI)": "MD 1.2 lower (2.37 lower to 0.03 lower)"
    },
    "Certainty": "  VERY LOW",
    "Importance": "CRITICAL"
  },
  "Remission (follow up: 4 months; assessed with: DAS28-ESR <2.6)": {
    "No of studies": [
      "5"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": [
      "very serious",
      "f"
    ],
    "Other considerations": "none",
    "No of patients": {
      "Switch to a 2nd TNFi": [
        "8/13 (61.5%)",
        "c"
      ],
      "Continue 1st TNFi": [
        "2/14 (14.3%)",
        "d"
      ]
    },
    "Effect": {
      "Relative (95% CI)": "RR 4.31 (1.11 to 16.67)",
      "Absolute (95% CI)": "473 more per 1,000 (from 16 more to 1,000 more)"
    },
    "Certainty": "  VERY LOW",
    "Importance": "CRITICAL"
  },
  "Radiographic progression (follow up: 4 months; assessed with: Sharp/ van der Heijde)": {
    "No of studies": [
      "5"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "serious",
      "g"
    ],
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": [
      "very serious",
      "h"
    ],
    "Other considerations": "none",
    "No of patients": {
      "Switch to a 2nd TNFi": [
        "12",
        "c"
      ],
      "Continue 1st TNFi": [
        "12",
        "d"
      ]
    },
    "Effect": {
      "Relative (95% CI)": "-",
      "Absolute (95% CI)": "MD 0.6 higher (1.78 lower to 2.98 higher)"
    },
    "Certainty": "  VERY LOW",
    "Importance": "IMPORTANT"
  },
  "Serious adverse events (follow up: 4 months)": {
    "No of studies": [
      "5"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": [
      "very serious",
      "b"
    ],
    "Other considerations": "none",
    "No of patients": {
      "Switch to a 2nd TNFi": [
        "0/13 (0.0%)",
        "c"
      ],
      "Continue 1st TNFi": [
        "2/14 (14.3%)",
        "d"
      ]
    },
    "Effect": {
      "Relative (95% CI)": "RR 0.21 (0.01 to 4.08)",
      "Absolute (95% CI)": "113 fewer per 1,000 (from 141 fewer to 440 more)"
    },
    "Certainty": "  VERY LOW",
    "Importance": "IMPORTANT"
  },
  "Serious adverse events (from SR of harms)": {
    "No of studies": [
      "3",
      "6"
    ],
    "content": "The Systematic Review RefID=5595, 2011 comparing Infliximab vs Etanercept among RA and AS, Psoriasis, PsA, IBD, Cancer showed that for Serious adverse events, the result was OR=0.93 (0.60 to 1.42). The Systematic Review RefID=1403, 2017 comparing Infliximab vs Etanercept among RA showed that for Serious adverse events, the result was RR=4.90 (0.23 to 104) [Direct Evidence, Low certainty].",
    "Importance": "IMPORTANT"
  },
  "Withdrawal due to adverse events (follow up: 4 months)": {
    "No of studies": [
      "5"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": "not serious",
    "Imprecision": [
      "very serious",
      "b"
    ],
    "Other considerations": "none",
    "No of patients": {
      "Switch to a 2nd TNFi": [
        "2/13 (15.4%)",
        "c"
      ],
      "Continue 1st TNFi": [
        "1/14 (7.1%)",
        "d"
      ]
    },
    "Effect": {
      "Relative (95% CI)": "RR 2.15 (0.22 to 21.03)",
      "Absolute (95% CI)": "82 more per 1,000 (from 56 fewer to 1,000 more)"
    },
    "Certainty": "  VERY LOW",
    "Importance": "IMPORTANT"
  }
}